LONDON and NEW YORK—MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company that initially focused on eye health, has closed its initial public offering of 5 million ordinary shares at a public offering price of $15 per share. The gross proceeds to MeiraGTx, before underwriting discounts and commissions, are $75 million, according to an announcement earlier this week. All of the ordinary shares in the offering were sold by MeiraGTx. MeiraGTx’s ordinary shares commenced trading June 8 on the Nasdaq Global Select Market under the ticker symbol “MGTX.”

MeiraGTx has four ongoing clinical programs and a broad pipeline of preclinical and research programs. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

BofA Merrill Lynch, Barclays and Evercore ISI acted as joint book-running managers for the offering, according to the announcement. Chardan acted as the lead manager for the offering.